T1	Parsing_Error 0 2	1.
T2	Parsing_Error 37 39	2.
T3	Parsing_Error 77 79	3.
T4	Parsing_Error 155 157	1.
T5	Parsing_Error 215 217	2.
T6	Parsing_Error 470 472	3.
T7	Parsing_Error 543 545	4.
T8	Parsing_Error 577 579	5.
T9	Parsing_Error 856 858	6.
T10	Parsing_Error 919 921	7.
T11	Person 3 7	Male
T12	Person 11 17	female
*	OR T12 T11
T13	Value 19 30	18-75 years
T14	Person 25 34	years old
R1	Has_value Arg1:T14 Arg2:T13	
T15	Measurement 59 68	WHO Group
T16	Value 69 70	1
R2	Has_value Arg1:T15 Arg2:T16	
T17	Condition 71 74	PAH
R3	AND Arg1:T17 Arg2:T15	
T18	Procedure 80 107	Right heart catheterization
T19	Parsing_Error 80 153	Right heart catheterization performed at Screening with results that are:
T20	Temporal 108 130	performed at Screening
T21	Reference_point 121 130	Screening
R4	Has_index Arg1:T20 Arg2:T21	
R5	Has_temporal Arg1:T18 Arg2:T20	
T22	Measurement 158 190	Mean pulmonary arterial pressure
T23	Value 191 199	≥25 mmHg
R6	Has_value Arg1:T22 Arg2:T23	
T24	Qualifier 201 208	at rest
R7	Has_qualifier Arg1:T22 Arg2:T24	
T25	Condition 218 247	Pulmonary venous hypertension
T26	Measurement 261 302	pulmonary capillary wedge pressure (PCWP)
T27	Value 303 311	≤15 mmHg
R8	Has_value Arg1:T26 Arg2:T27	
R9	AND Arg1:T25 Arg2:T26	
T28	Condition 344 369	mean left atrial pressure
T29	Condition 373 412	left ventricular end-diastolic pressure
T30	Value 413 421	≤15 mmHg
R10	Has_value Arg1:T29 Arg2:T30	
R11	Has_value Arg1:T28 Arg2:T30	
*	OR T29 T28
T31	Negation 429 436	absence
T32	Condition 440 463	left atrial obstruction
R12	Has_negation Arg1:T32 Arg2:T31	
T33	Condition 473 508	Pulmonary vascular resistance (PVR)
T34	Value 509 523	≥300 dyn•s/cm5
T35	Value 525 540	3.75 Wood units
R13	Subsumes Arg1:T34 Arg2:T35	
R14	Has_value Arg1:T33 Arg2:T34	
T36	Measurement 550 561	WHO/NYHA-FC
T37	Value 565 567	II
T38	Value 571 574	III
*	OR T38 T37
T39	Scope 565 574	II or III
R15	Has_scope Arg1:T36 Arg2:T39	
T40	Qualifier 586 597	stable dose
T41	Multiplier 601 613	at least one
T42	Procedure 631 653	PAH-specific therapies
T43	Drug 655 685	endothelin receptor antagonist
T44	Drug 690 730	agent acting on the nitric oxide pathway
T45	Drug 732 766	phosphodiesterase type 5 inhibitor
T46	Drug 770 806	soluble guanylate cyclase stimulator
*	OR T46 T45
T47	Scope 732 806	phosphodiesterase type 5 inhibitor or soluble guanylate cyclase stimulator
R16	Subsumes Arg1:T44 Arg2:T47	
T48	Drug 818 830;847 853	prostacyclin analog
T49	Drug 834 853	prostacyclin analog
*	OR T43 T44 T49 T48
T50	Scope 655 853	endothelin receptor antagonist, an agent acting on the nitric oxide pathway (phosphodiesterase type 5 inhibitor or soluble guanylate cyclase stimulator), and/or a prostacyclin or prostacyclin analog
R17	Subsumes Arg1:T42 Arg2:T50	
R18	Has_multiplier Arg1:T42 Arg2:T41	
R19	Has_qualifier Arg1:T42 Arg2:T40	
T51	Measurement 865 887	6-minute walk distance
T52	Value 896 916	≥150 and ≤500 meters
R20	Has_value Arg1:T51 Arg2:T52	
T53	Procedure 929 955	ventilation-perfusion scan
T54	Condition 971 993	thromboembolic disease
T56	Negation 961 970	rules out
R21	Has_negation Arg1:T54 Arg2:T56	
R22	AND Arg1:T54 Arg2:T53	
